MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage small ...
The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending. In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results